NasdaqCM - Nasdaq Real Time Price USD

Ainos, Inc. (AIMD)

0.5801

-0.1299

(-18.30%)

At close: January 13 at 4:00:02 PM EST

Ainos Unveils AI Nose for Robotics: Invites Global Robotics Companies to Join Forces in Shaping the Future of Smell-Enabled Robots

Ainos invites robotics and humanoid companies to join Ainos Alliance and digitize smell SAN DIEGO, CA / ACCESSWIRE / January 13, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW), a pioneer of digitizing scent, proudly announces its revolutionary AI ...

ACCESSWIRE 19 hours ago

AIMD
-18.30%
AIMDW
CORRECTION BY SOURCE: Smell the Future: Ainos Elevates Health and Technology With AI Nose and VELDONA

SAN DIEGO, CA / ACCESSWIRE / December 18, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on novel AI-powered point-of-care testing ("POCT") and VELDONA ® low-dose interferon therapeutics, ...

ACCESSWIRE 26 days ago

AIMD
-18.30%
AIMDW
Smell the Future: Ainos Elevates Health and Technology With AI Nose and VELDONA

Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on novel AI-powered point-of-care testing ("POCT") and VELDONA ® low-dose interferon therapeutics, is pleased to provide a letter to shareholders ...

ACCESSWIRE 26 days ago

AIMD
-18.30%
AIMDW
Ainos Joins Webull Corporate Connect Service Platform to Enhance Investor Engagement

SAN DIEGO, CA / ACCESSWIRE / December 13, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, ...

ACCESSWIRE last month

AIMD
-18.30%
AIMDW
Water Tower Research Underscores Ainos' Partnership With Taiwan Tanabe Seiyaku for VELDONA Manufacturing and Marketing

SAN DIEGO, CA / ACCESSWIRE / December 4, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, ...

ACCESSWIRE last month

AIMD
-18.30%
AIMDW
Ainos, Inc. Announces Strategic Partnership with Taiwan Tanabe Seiyaku to Advance Manufacturing and Taiwan Market Promotion of Sjögren's Syndrome Drug

San Diego, California--(Newsfile Corp. - December 2, 2024) - Ainos, Inc. (NASDAQ: AIMD) (NASDAQ: AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, today proudly announced the signing of a strategically significant Memorandum of Understanding (MOU) with Taiwan Tanabe Seiyaku Co., Ltd., a subsidiary of Mitsubishi Tanabe Pharma Corporation in Japan, brings extensive pharmaceutical de

Newsfile last month

AIMD
-18.30%
AIMDW
Water Tower Research Highlights IRB Approval for the Ainos VELDONA Clinical Sjogren's Trial Alongside 3Q24 Earnings and Developments

Taiwan regulatory approval for the trial expected in Q1 2025 Remains committed to a capital-efficient business strategy SAN DIEGO, CA / ACCESSWIRE / November 13, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative ...

ACCESSWIRE last month

AIMD
-18.30%
AIMDW
Ainos Announces IRB Approval for Sjögren’s Syndrome Clinical Study at Shuang Ho Hospital, Affiliated with Taipei Medical University, and Plans to Initiate New Phase of Treatment Evaluation in Q1 2025

IRB approval on track as scheduled Next step is obtaining all regulatory approvals, followed by site initiation visit VELDONA significantly increases unstimulated whole salivary flow in prior Phase 3 studies SAN DIEGO, CA / ACCESSWIRE / November 11, ...

ACCESSWIRE 2 months ago

AIMD
-18.30%
AIMDW
Ainos Third Quarter 2024 Earnings: US$0.33 loss per share (vs US$0.73 loss in 3Q 2023)

Ainos ( NASDAQ:AIMD ) Third Quarter 2024 Results Key Financial Results Net loss: US$3.70m (loss widened by 24% from 3Q...

Simply Wall St. 2 months ago

AIMD
-18.30%
AIMDW
Ainos Takes Decisive Action to Protect Stockholder Interests and Combat Potential Illegal Trading Activities

SAN DIEGO, CA / ACCESSWIRE / November 8, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-powered point-of-care testing (POCT) and low-dose interferon therapeutics, ...

ACCESSWIRE 2 months ago

AIMD
-18.30%
AIMDW
Ainos Reports Third Quarter 2024 Financial Results

Secured multi-regional patent assets, strengthening Ainos' AI Nose technology. Expanded VELDONA® patent portfolio with a new invention patent for treatments and preventions for coronavirus infections. Progressed clinical trials for VELDONA®, including ...

ACCESSWIRE 2 months ago

AIMD
-18.30%
AIMDW
Ainos Expands Patent Portfolio With Strategic Shareholder’s Cutting-Edge Technology Assets

Strengthens AI Nose Gas Sensing Technology with Additional Exclusively Licensed Patents Secures Exclusive Rights to Breakthrough Nitrogen-Oxygen Separation Technology with Superior Energy Efficiency and Ultra-Low Carbon Emissions, Advancing Sustainable ...

ACCESSWIRE 2 months ago

AIMD
-18.30%
AIMDW
Ainos Highlights VELDONA Clinical Advancements and Market Potential in Water Tower Research Spotlight Podcast

Prioritizing VELDONA®'s development for oral warts in HIV+ patients and Sjogren's syndrome Burgeoning pet care market also presents growth opportunities for VELDONA® SAN DIEGO, CA / ACCESSWIRE / October 24, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ...

ACCESSWIRE 2 months ago

AIMD
-18.30%
AIMDW
Ainos Advances Healthcare and Industrial Innovations with AI Nose and VELDONA Technologies

Ainos pioneers AI-powered digital nose technology with VOC detection breakthroughs for early disease diagnosis, industrial safety, and human-like sensory capabilities in robots VELDONA® low-dose oral interferon technology demonstrates huge potential ...

ACCESSWIRE 3 months ago

AIMD
-18.30%
AIMDW
Ainos, Inc. Receives IRB Approval From National Taiwan University Hospital for HIV-Oral Warts Clinical Trial, Highlighting Value of FDA-Designated Orphan Drug VELDONA

Next step will be receiving approval from Taiwan Food and Drug Administration (TFDA) SAN DIEGO, CA / ACCESSWIRE / September 25, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on ...

ACCESSWIRE 3 months ago

AIMD
-18.30%
AIMDW
Ainos Spotlighted in Water Tower Research Report on VELDONA Clinical Study for Sjogren’s Syndrome

Sjogren's Syndrome is a rare autoimmune disease with limited treatment options Prior U.S. Phase 3 data demonstrated benefits SAN DIEGO, CA / ACCESSWIRE / September 24, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative ...

ACCESSWIRE 3 months ago

AIMD
-18.30%
AIMDW
Ainos Announced Plan to Initiate Taiwan Clinical Study of VELDONA for Treating Sjögren's Syndrome, a Rare Disease With Limited Treatment Options

Prior Phase 3 studies showed positive benefits in increasing unstimulated whole saliva secretion Ainos aims to complete all regulatory approvals for the study in Q4 2024 SAN DIEGO, CA / ACCESSWIRE / September 23, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ...

ACCESSWIRE 3 months ago

AIMD
-18.30%
AIMDW
Water Tower Research Highlights Ainos VELDONA Clinical Trial for HIV+ Patients with Oral Warts

SAN DIEGO, CA / ACCESSWIRE / September 20, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, ...

ACCESSWIRE 3 months ago

AIMD
-18.30%
AIMDW
Ainos Announced Plan to Initiate Taiwan Clinical Study for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA

Ainos Plans To Conduct the Study at National Taiwan University Hospital, a Premier Taiwanese Medical Center for HIV Management The U.S. FDA Have Granted Orphan Drug Designation (ODD) for the Company's VELDONA® Low-Dose Oral Interferon Formulation ...

ACCESSWIRE 3 months ago

AIMD
-18.30%
AIMDW
Ainos Secures Taiwan Invention Patent and Advances Global Patent Protection for VELDONA, a Breakthrough in Coronavirus Treatment and Prevention

This patent marks a major leap in Ainos' antiviral research, contributing to global efforts against coronavirus infections SAN DIEGO, CA / ACCESSWIRE / September 3, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative ...

ACCESSWIRE 4 months ago

AIMD
-18.30%
AIMDW

Performance Overview

Return	AIMD	S&P 500
YTD	+27.49%	-1.20%
1-Year	-64.19%	+22.00%
3-Year	-98.71%	+23.48%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Ainos, Inc. (AIMD)

Ainos Unveils AI Nose for Robotics: Invites Global Robotics Companies to Join Forces in Shaping the Future of Smell-Enabled Robots

CORRECTION BY SOURCE: Smell the Future: Ainos Elevates Health and Technology With AI Nose and VELDONA

Smell the Future: Ainos Elevates Health and Technology With AI Nose and VELDONA

Ainos Joins Webull Corporate Connect Service Platform to Enhance Investor Engagement

Water Tower Research Underscores Ainos' Partnership With Taiwan Tanabe Seiyaku for VELDONA Manufacturing and Marketing

Ainos, Inc. Announces Strategic Partnership with Taiwan Tanabe Seiyaku to Advance Manufacturing and Taiwan Market Promotion of Sjögren's Syndrome Drug

Water Tower Research Highlights IRB Approval for the Ainos VELDONA Clinical Sjogren's Trial Alongside 3Q24 Earnings and Developments

Ainos Announces IRB Approval for Sjögren’s Syndrome Clinical Study at Shuang Ho Hospital, Affiliated with Taipei Medical University, and Plans to Initiate New Phase of Treatment Evaluation in Q1 2025

Ainos Third Quarter 2024 Earnings: US$0.33 loss per share (vs US$0.73 loss in 3Q 2023)

Ainos Takes Decisive Action to Protect Stockholder Interests and Combat Potential Illegal Trading Activities

Ainos Reports Third Quarter 2024 Financial Results

Ainos Expands Patent Portfolio With Strategic Shareholder’s Cutting-Edge Technology Assets

Ainos Highlights VELDONA Clinical Advancements and Market Potential in Water Tower Research Spotlight Podcast

Ainos Advances Healthcare and Industrial Innovations with AI Nose and VELDONA Technologies

Ainos, Inc. Receives IRB Approval From National Taiwan University Hospital for HIV-Oral Warts Clinical Trial, Highlighting Value of FDA-Designated Orphan Drug VELDONA

Ainos Spotlighted in Water Tower Research Report on VELDONA Clinical Study for Sjogren’s Syndrome

Ainos Announced Plan to Initiate Taiwan Clinical Study of VELDONA for Treating Sjögren's Syndrome, a Rare Disease With Limited Treatment Options

Water Tower Research Highlights Ainos VELDONA Clinical Trial for HIV+ Patients with Oral Warts

Ainos Announced Plan to Initiate Taiwan Clinical Study for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA

Ainos Secures Taiwan Invention Patent and Advances Global Patent Protection for VELDONA, a Breakthrough in Coronavirus Treatment and Prevention

Performance Overview